r Bone Metabolism and Disease
in Chronic Kidney Disease. National Kidney Foundation. Accessed June
17, 2004.
(8) http://www.emedicine.com/emerg/topic266.htm . “Hyperphosphatemia,”
by Leigh A Patterson, MD, Staff Physician, Department of Emergency
Medicine, Charity Hospital, Louisiana State University, December 11,
2001.
(9) http://www.kidney.org/professionals/kdoqi/guidelines_bone/
background.htm .
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease
in Chronic Kidney Disease. National Kidney Foundation. Accessed June
22, 2004.
(10) Molowa DT. First annual nephrology survey. JP Morgan Securities
Inc., Equity Research, February 13, 2002.
(11) USRDS 2004 Annual Data Report: Atlas of End Stage Renal Disease in
the United States. U.S. Renal Data System, National Institutes of
Health, National Institute of Diabetes & Digestive & Kidney Diseases,
Bethesda, MD, 2003, page 75.
(12) http://www.emedicine.com/emerg/topic266.htm . “Hyperphosphatemia,”
by Leigh A Patterson, MD, Staff Physician, Department of Emergency
Medicine, Charity Hospital, Louisiana State University, December 11,
2001.
(13) http://www.emedicine.com/emerg/topic266.htm . “Hyperphosphatemia,”
by Leigh A Patterson, MD, Staff Physician, Department of Emergency
Medicine, Charity Hospital, Louisiana State University, December 11,
2001.
(14) Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum
phosphorus and calcium x phosphate product with mortality risk in
chronic hemodialysis patients: A national study. Am J. Kidney Dis
1998; 31:607-617.
(15) Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum
phosphorus and calcium x phosphate product with mortality risk in
chronic hemodialysis patients: A national study. Am J. Kidney Dis
|
